Abstract
Recently, the management of chronic hepatitis C virus (HCV) has been greatly advanced with introduction of direct acting antivirals (DAAs) in clinical setting. The Japan Society of Hepatology (JSH) first released the clinical practice guideline for the management of HCV infection in 2012, and revised in 2013 along with the introduction of a second-generation DAA, simeprevir (SMV). In September 2014, the first IFN-free DAAs, daclatasvir (DCV) and asunaprevir (ASV), were launched and the antiviral therapy for IFN intolerant/ineligible patients became to be possible. Thence the society has now revised the clinical practice guidelines at this time, and added a new treatment flow-chart for the antiviral therapy in patients with cirrhosis. In this article I summarized the revised guidelines and would like to introduce the treatment recommendations.
| Original language | English |
|---|---|
| Pages (from-to) | 221-227 |
| Number of pages | 7 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 73 |
| Issue number | 2 |
| State | Published - 1 Feb 2015 |
